Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

From geopolitical conflicts to cyber threats, CDMOs must rethink resilience.

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Researchers develop a new platform to improve delivery of oligonucleotide therapies to muscle.

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.